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Background: Screening can reduce colorectal cancer (CRC) incidence and mortality. However, screening is
underutilized in vulnerable patient populations, particularly among Latinos. Patient-directed decision aids can
increase CRC screening knowledge, self-efficacy, and intent; however, their effect on actual screening test
completion tends to be modest. This is probably because decision aids do not address some of the patient-specific
barriers that prevent successful completion of CRC screening in these populations. These individual barriers might
be addressed though patient navigation interventions. This study will test a combined decision aid and patient
navigator intervention on screening completion in diverse populations of vulnerable primary care patients.
Methods/Design: We will conduct a multisite, randomized controlled trial with patient-level randomization. Planned
enrollment is 300 patients aged 50 to 75 years at average CRC risk presenting for appointments at two primary clinics
in North Carolina and New Mexico. Intervention participants will view a video decision aid immediately before the clinic
visit. The 14 to 16 minute video presents information about fecal occult blood tests and colonoscopy and will be
viewed on a portable computer tablet in English or Spanish. Clinic-based patient navigators are bilingual and bicultural
and will provide both face-to-face and telephone-based navigation. Control participants will view an unrelated food
safety video and receive usual care. The primary outcome is completion of a CRC screening test at six months. Planned
subgroup analyses include examining intervention effectiveness in Latinos, who will be oversampled. Secondarily,
the trial will evaluate the intervention effects on knowledge of CRC screening, self-efficacy, intent, and
patient-provider communication. The study will also examine whether patient ethnicity, acculturation, language
preference, or health insurance status moderate the intervention effect on CRC screening.
Discussion: This pragmatic randomized controlled trial will test a combined decision aid and patient navigator
intervention targeting CRC screening completion. Findings from this trial may inform future interventions and
implementation policies designed to promote CRC screening in vulnerable patient populations and to reduce
screening disparities.
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Colorectal cancer screening in vulnerable populations
Colorectal cancer (CRC) is an important cause of cancer
death among all men and women in the United States,
including Latinos [1,2]. Compared with non-Latinos,
Latinos have substantially lower CRC screening rates
and may also be more likely to be diagnosed with CRC
at an advanced stage [1,3,4]. Despite increases in screening
rates in the last decade [5], only 65% of US adults are up
to date with recommended screening, and only about 47%
of US Latino adults [6,7]. Members of vulnerable groups,
including racial or ethnic minorities, the uninsured, and
Medicaid populations have the lowest screening rates in
the USA [8]. The many patient-, provider-, and system-
level barriers that inhibit the CRC screening process
disproportionately affect vulnerable groups. Common
barriers to completing screening include poor know-
ledge about screening and screening options, compet-
ing demands in primary care, leading to insufficient
communication with the provider about screening, lack
of health insurance (resulting in a lack of access to
care, including cancer screening), and an inability to
navigate the healthcare system (resulting in screening
not being scheduled or completed). Latinos, now one
of the nation’s largest racial or ethnic minority groups,
often face additional language (communicating with
providers about screening) and cultural barriers (mach-
ismo, fatalism) [8-10]. To increase CRC screening in vul-
nerable populations, interventions that address multiple
screening barriers are needed. Moreover, to address ethnic
disparities in CRC screening, these interventions must be
effective in Latino populations.
Successful CRC screening requires multiple steps
Successful completion of CRC screening in primary care
requires progression through a number of steps: having
awareness of and knowledge about screening, deciding
that one is ready for screening (intent), having self-
efficacy to discuss screening with a provider, and ability
to communicate effectively and form a screening plan
with a provider. Later steps in the progression include
movement from test ordering to test completion. Fail-
ures in CRC screening may occur from ‘breakdowns’ of
the process at any one of these steps [11,12]. Vulnerable
populations are particularly susceptible to such break-
downs, owing to barriers at the levels of the healthcaresystem and providers, including a lack of access to care
and decreased physician time during a visit [13,14]. At
the individual level, many factors affect screening uptake,
particularly in vulnerable immigrant populations, includ-
ing: acculturation and language barriers; sociocultural
beliefs, such as cancer fatalism; and lack of knowledge
and low health literacy [9,15-18].
Decision aids and patient navigation
Decision aids are evidence-based patient education tools
designed to promote informed and shared health-related
decision making [19]. Decision aids for CRC screening
have the potential to mitigate some of the barriers to
screening. For example, decision aids can overcome lit-
eracy barriers by having a narrator read all text aloud
or by using easy-to-understand graphics and anima-
tions. Because they can be viewed outside of the actual
patient-provider encounter and can be delivered by
other members of the healthcare team, decision aids can
also help to overcome provider barriers, such as lack of
time to educate patients about screening. Decision aids
are designed not only to help patients gain knowledge and
build intent, but also to help patients understand their
options and prepare them to engage in making in-
formed decisions with their healthcare providers [20].
Studies in English-speaking populations have shown
that decision aids can increase patients’ knowledge about
cancer and screening, intent to be screened, ability to
state a CRC screening test preference, and even screening
completion [21-24]. A preliminary study of the Spanish-
language decision aid used in this study suggests that the
decision aid is efficacious; decision specific knowledge
about CRC screening, and self-efficacy and intention to
complete CRC screening all improved. It also suggested
that the decision aid improved communication between
doctor and patient about CRC screening [25]. However,
the overall body of evidence is mixed regarding the effect
of decision aids as a single intervention on CRC screening
test completion. This suggests that while decision aids
educate and activate patients, other barriers that inhibit
the progression to test completion are not addressed by
decision aids alone.
Introduced in the 1990s, patient navigation has been
advocated as an approach to addressing barriers to cancer
care (including cancer screening) for vulnerable popula-
tions [26,27]. Experts currently define patient navigation
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to individual patients for a specific episode of cancer-
related care; (b) has a defined endpoint, when an episode
of care is complete (for example, CRC screening); (c) tar-
gets a defined set of health services required to complete
an episode of cancer-related care; and (d) focuses on in-
dividual barriers to accessing cancer care [28]. Emerging
evidence supports the effectiveness of patient navigation
in increasing cancer screening in general and, specifically,
in increasing CRC screening in vulnerable populations
[29,30]. Decision aids and patient navigators represent
potentially complementary interventions for promoting
screening because they address multiple barriers that
affect different steps in the screening process. Combing
the two intervention methods might be a more effective
way to address the complex, multilevel barriers to CRC
screening that vulnerable populations encounter. How-
ever, to our knowledge, no study has tested an interven-
tion combining a decision aid with patient navigation to
promote CRC screening in vulnerable populations in a
primary care setting.
Conceptual framework
Informed by Prochaska’s transtheoretical model and
‘stages of change’ and Bandura’s social cognitive theory
[31,32], our conceptual framework (Figure 1) illus-
trates the steps involved in CRC screening and how we
hypothesize that the components of our intervention
will affect the process. The decision aid acts mainly to
increase patient knowledge, self-efficacy, and intent,
and promotes informed decision making regarding
choice of screening modality and communication with
a healthcare provider. The patient navigator primarily
facilitates completion of screening by addressing additional
barriers that often supervene even after a screening test
has been ordered. However, a patient navigator may also
help to build on the knowledge, intent, and self-efficacy
established by decision aid viewing.
Study objectives
The specific objectives of this study are:
1. To determine the effect, relative to usual care, of a
practice-based intervention that includes a CRC
screening decision aid plus patient navigation on
CRC screening completion in diverse, vulnerable
primary care patient populations.
2. To determine (a) the intervention effect on
knowledge, self-efficacy, intent, and clinical
communication about CRC screening and (b) how
these factors influence the effectiveness of the
intervention on screening test completion.
3. To explore whether patient ethnicity, acculturation,
language preference, or health insurance statusmoderate the relationship between the intervention
and screening behavior.
Our main hypotheses are that an intervention includ-
ing a CRC screening decision aid combined with bilin-
gual and bicultural patient navigators will improve
patients’ screening-related knowledge and self-efficacy,
promote intention to be screened and patient-provider
communication about screening, facilitate test order-
ing, and result in a significant increase in successful
completion of CRC screening.
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Overview of study design
As illustrated in Figure 1, the CHOICES/OPCIONES
trial is a multisite, two-arm pragmatic randomized con-
trolled trial testing the effect of an intervention, including
a CRC screening decision aid and a patient navigator, in
primary care clinics serving diverse, vulnerable patients.
The combination of two interventions represents a novel
approach to promoting cancer screening in vulnerable
populations. The primary outcome is CRC screening
test completion at six months. Secondary outcomes in-
clude CRC screening knowledge, screening self-efficacy,
intention to be screened, and patient-provider commu-
nication about CRC screening. This study is approved
by the Institutional Review Boards at the University of
North Carolina (Study # 09–0537), the University of
New Mexico (Study ID 12–263), and the Carolinas
HealthCare System (File # 12-13-03E).
Study participants and setting
The trial will recruit approximately 300 participants, in-
cluding at least 150 Latinos from the two clinic sites
over approximately 15 months. Enrolled patients will be
aged 50 to 75 years, at average risk of CRC, and not cur-
rently undergoing CRC screening according to current
US Preventive Services Task Force recommendations
[33]. Patients will be excluded if they are unable to speak
either English or Spanish, or have severe cognitive, visual,
or hearing impairment that would prevent decision aid
viewing. Research assistants will review the appointment
schedule and medical records to identify potentially eli-
gible participants prior to or on the day of a visit. After de-
termining eligibility, interested participants will complete
a signed consent form and provide authorization under
the terms of the Health Insurance Portability and Ac-
countability Act.
The two study sites are in Charlotte, North Carolina
and Albuquerque, New Mexico, and are parts of larger,
non-profit healthcare systems. Both sites serve racially
and ethnically diverse, low-income communities. The
Charlotte, NC, site is a Community Health Center in
northeast Charlotte. The clinic serves approximately
12,000 patients, among whom there is a large and growing
Latino population. The clinic site in Albuquerque, NM, is
located in the International District of Albuquerque, the
most densely populated and ethnically diverse sector of
the city. The clinic serves more than 5,000 patients, nearly
half of whom are Latino.
Randomization and blinding
The trial will randomize individual patients, stratified by
site, in a 1:1 ratio of intervention to control using ran-
domly permuted blocks with random block sizes. The
coordinating site (the University of North Carolina) willproduce, for each study site, sequentially numbered,
sealed, opaque envelopes containing the randomized
arm assignments. The research assistants, who will
not know the randomization scheme, will perform the
randomization by opening the envelopes sequentially
as they enroll study participants. Health care providers
at the clinic sites will not be actively notified of patient
enrollment in the study. For budgetary reasons, the re-
search assistant conducting the enrollment and index
visit data collection will also be the patient navigator,
and therefore it is not feasible to blind the research assist-
ant to treatment assignment after randomization occurs.
However, a separate, blinded member of the research team
will determine the primary study outcome of CRC screen-
ing test completion (based on medical record review at six
months). In addition, the study biostatistician will program
the primary models for addressing each of the aims using
dummy treatment assignments and will remain blinded to
actual treatment assignments until the models, along with
any related assumptions, have been assessed and finalized.
Intervention and comparison
Participants randomized to the intervention group will re-
ceive a combined intervention consisting of CRC screen-
ing decision aid and assistance from a trained patient
navigator. Participants in the control group will view an
attention control video about food safety in their preferred
language (English or Spanish) prior to the provider visit
and usual care. We chose to use an attention control video
so that the structure of the control arm mirrored the
intervention arm. The food safety topic was chosen to
provide information that is reasonably salient to the con-
trol arm participants but that would not be likely to affect
conversation during the physician encounter.
Decision aid
The decision aid is available in both English and Spanish.
The English version was developed and tested rigorously,
and has been continually revised and updated to reflect
changes in evidence [22,34]. The Spanish version was
adapted from the English version using a rigorous cultural
and linguistic adaptation and evaluation process [25,35].
The decision aids are 14 to 16 minute long videos and
were developed to promote CRC screening, while pre-
senting a balanced view about the choice of screening
modality (colonoscopy versus fecal occult blood test-
ing). Participants assigned to the intervention group will
view the decision aid prior to the physician visit. Both
the English and Spanish versions are designed to be access-
ible across all literacy levels by using easy-to-understand
narration, vignettes, graphics and animations. Patients are
introduced to the rationale of CRC screening and the two
most widely available screening modalities (colonoscopy
and fecal occult blood testing), and the key attributes of
Table 1 Time points for principal measures
Domain Timing
Baseline Post
encounter
6 months
Demographics and covariates ×
Knowledge about screening × × ×
Acculturation ×
Patient-provider communication ×
Intention to be screened × ×
Self-efficacy × ×
Screening completion ×
Navigation process × ×
Navigation satisfaction ×
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testing, discomfort, costs, risks, and effectiveness. At the
end of each decision aid, the viewer is prompted to choose
a brochure with a traffic light color scheme that signals his
or her readiness to be screened, informed by Prochaska’s
transtheoretical model (red, pre-contemplation; yellow,
contemplation; green, action) [22,31].
Patient navigation
The second component of the intervention is navigation
by a trained bilingual and bicultural patient navigator.
Navigation will involve both initial face-to-face contact
and semistructured phone contact. The role of the patient
navigator will be to help patients overcome barriers to
completion of CRC screening. The patient navigator will
briefly meet the participant after the provider encounter
to find out if screening decisions were made and if assist-
ance in carrying out the screening plan is needed. The pa-
tient navigator will then attempt to contact intervention
participants at two weeks and (at the patient navigator’s
discretion) up to four additional times, as necessary, after
the clinic visit to assist with screening test completion.
Specific counseling will be tailored based on individual pa-
tient factors, including choice of test strategy (fecal occult
blood testing or colonoscopy), follow-up appointments
(including a follow-up colonoscopy for a positive fecal oc-
cult blood test), screening barriers, and stage of readiness
for screening. For example, a patient who is considering
screening (contemplation) might not have received a fecal
occult blood testing kit at the index visit, but may later
wish to receive the cards by mail. Another patient who is
ready for screening (preparing for action) might have had
a colonoscopy ordered by the provider, but may be having
difficulty understanding how to schedule an appointment,
or how to complete the bowel preparation procedure.
Data collection and measures
Overview
Data collection will take place at three time points: base-
line, immediately after the physician visit, and at six
months after the initial study visit. Measures and timing
of measures are shown in Table 1. Patient questionnaires
will be administered orally in English or Spanish.
Primary outcome
The primary outcome of this study will be completion of
a CRC screening test within six months after the initial
study visit. Screening test completion will be assessed
through a blinded medical record review. Patients will
be considered current with screening if there is evidence
of completion of a recommended screening test includ-
ing home fecal occult blood testing, flexible sigmoidos-
copy, or colonoscopy. We will record screening modality
and results for all tests. For positive fecal occult bloodtests, screening will not be considered ‘completed’ unless
a follow-up colonoscopy is completed or is pending.
Secondary outcomes and other measures
Baseline measures will capture demographics, insurance
status, health literacy, language preference, and accultur-
ation (Latinos only). We will also assess CRC knowledge,
self-efficacy, and intention to be screened at baseline,
using measures from our preliminary studies [25]. Imme-
diately after the provider visit, we will re-assess knowledge,
self-efficacy, and intention to be screened, as well as
provider-patient communication about CRC screening. At
six months, we will re-assess knowledge, self-efficacy, and
intention to be screened in the future.
Analytic approach and power
Analyses
We will follow the intention-to-treat principle for all
analyses. Our analysis of the primary hypothesis will be
a direct, unadjusted comparison of proportions screened
in intervention versus control arms using a Mantel-
Haenszel χ-squared test, controlling for site, conducted
at the 0.05 significance level. Latino participants will be
examined in a separate subgroup analysis. If substantial
differences known to be associated with CRC screening
are present at baseline between the intervention and
control arms, multiple logistic regression analysis will be
used to adjust for these variables. We will, similarly, use
logistic regression models to explore whether ethnicity,
patient language preference, or health insurance moderate
the relationship between the intervention and screening
behavior by testing appropriate interaction terms, each at
the 0.05 significance level. If any interaction is significant,
the intervention will be tested within the respective
subgroups using the model with appropriate contrast
statements.
To address the second objective, we will apply a struc-
tural equation model (specifically, a path analysis with
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propriately for their scale (that is, knowledge will be or-
dinal, while self-efficacy, intent, and communication
will be categorical). The model will use data from all
patients and will control for baseline knowledge, self-
efficacy, intent, ethnicity, and site as exogenous vari-
ables. The primary model will include indirect effects of
the intervention on the outcome through the potential
mediating variables along with the direct effect, to allow
assessment of whether any mediation is complete or
partial. However, in the primary model, no structural
model will be imposed relating the mediating variables
to one another, beyond simple correlations. As a sup-
portive, secondary, analysis, we will also fit a model that
imposes the structural model depicted in Figure 2 and
will assess its fit using standard fit indices (that is, root
mean squared error of approximation, Bollen’s incremen-
tal index, and the Tucker-Lewis index). Nested models will
be compared using χ-squared difference tests at the
0.05 level.
Power calculations
We are planning to recruit at two clinics for 15 to
20 months each. We anticipate being able to enroll
about two or three patients per week at each clinic for a
total sample ranging from 250 to 380. This will provide
more than adequate power to answer the primary re-
search question of intervention effectiveness among all
participants and reasonable power to test the effective-
ness among Latino participants. If screening status is
assessed for at least 90% of enrolled participants, a sam-
ple size of 250 will provide at least 90% power to detect
a 20% difference in screening completion rate between
the groups, assuming equal group sizes, two-sided α of
0.05, and a 20% screening rate in the control group.
Under these same assumptions, enrolling 150 Latino
participants will provide at least 70% power to detect a
20% difference in screening completion rates.
Discussion
The CHOICES/OPCIONES trial will help fill several
gaps in our understanding of how to improve rates ofFigure 2 Conceptual model for the CHOICES/OPCIONES project.CRC screening among vulnerable populations. First, al-
though several trials have tested either patient navigation
or decision aid interventions to increase informed choice
and promote CRC screening, this will be the first clinical
trial, to our knowledge, to test a combination of the two
approaches [36-39]. Second, this trial will test a pragmatic
intervention delivered in a real-world clinic-based context.
In contrast with studies that deliver patient navigation
remotely (that is, only by telephone), this study will use bi-
lingual navigators who are encountered at the clinical site
and therefore likely to be viewed as part of the clinical
team. Thus, findings may have implications for clinical
and payment policies that facilitate incorporation of pa-
tient navigation for cancer screening into patient-centered
medical home models of care [40].
Third, this trial will advance scientific knowledge regard-
ing methods of overcoming cancer screening disparities
for Latino populations, who make up the largest and fast-
est growing racial or ethnic minority group in the USA
and who have substantially lower CRC screening rates
than non-Latinos. Fourth, by measuring how viewing a
cancer screening decision aid before a primary care visit
affects intermediate outcomes (screening-related know-
ledge, self-efficacy, intent, and communication with a
healthcare provider), the study will enhance our mech-
anistic understanding of how patient-directed interven-
tions affect communication, decision making, and
screening behavior. Specifically, the study will help elu-
cidate the causal role that these intermediate factors
play in mediating screening behavior. Understanding these
causal links is important in designing effective cancer
screening behavioral interventions.
Lastly, the exploratory aims of the study have the poten-
tial to shed light on how this kind of intervention interacts
with key patient-level demographic factors of health insur-
ance and language preference. These findings may inform
future research and policy questions, such as those related
to healthcare access for immigrant populations, and the
degree to which these kinds of intervention should target
Latino populations broadly, or should be focused more
specifically on the more vulnerable limited English profi-
ciency subpopulations.Trial status
This trial is currently enrolling participants. Data col-
lection began in January 2014, and will continue until
December 2015.Abbreviation
CRC: colorectal cancer.Competing interests
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